Navigation Links
First Human Implant of New Archus Orthopedics Facet Replacement System
Date:4/23/2008

REDMOND, Wash., April 23 /PRNewswire/ -- Archus Orthopedics, Inc., announced today that it has successfully completed the first human implant of its TFAS-C(TM) system, the newest addition to the company's product line for treating spinal stenosis, a condition in which degenerative changes in the facet joints result in compression of spinal nerves producing neurological symptoms in the legs. Traditionally, patients with moderate to severe spinal stenosis undergo decompressive laminectomy surgery, which is often accompanied by spinal fusion. Archus products replace degenerative facet joints with a prosthetic joint implant intended to restore stability and normal motion to the spine, eliminating the need for fusion.

The TFAS-C is indicated for the L3-4 and L4-5 spinal levels and complements the company's TFAS-LS(TM) system, which entered the clinic in late 2007 and addresses the unique anatomy of the L5-S1, "lumbosacral" spinal level. Both systems utilize conventional pedicle screw fixation and join the company's first product, the Total Facet Arthroplasty System(R) or "TFAS(R)", which is anchored by means of bone cement and has been successfully implanted in nearly two hundred patients worldwide, with the vast majority treated in the United States in an ongoing IDE study approved by the U.S. Food and Drug Administration.

The milestone case was performed in Europe by Dr. Scott Webb from the Florida Spine Institute, assisted by Dr. Radu Prejbeanu, Dr. Ioan Branea and Dr. Dinu Vermesan. "The TFAS-C is easy to implant and our first case was very straightforward," said Dr. Webb, a pioneering spine surgeon who performed the first TFAS implantation in 2005, which was one of the earliest facet joint replacement procedures ever completed. "The full product line that Archus has developed for spinal stenosis allows me to treat almost all comers and gives me multiple device options to address variable patient anatomy and pathology," he added.

"The TFAS
'/>"/>

SOURCE Archus Orthopedics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... , NEW YORK, Nov. 25 R...ch report is available in its catalogue: ,, Un...ecasts to 2015 ,, http://www.reportlinker.com...ysis-and-Forecasts-to-2015.html ,, United Stat... 2015 ,, Summary ,, This report is an esse...
(Date:11/25/2009)... , EAST BRUNSWICK, N.J., Nov. 25 /PRNewsw...ufacturer of direct digital Radiography ( ddR ) sy...en acquired by a private Swiss Investor with a lon...ging brand. The acquisition included all assets an...inventory. After 25 years of success and growth Sw...
(Date:11/25/2009)... , CHAPEL HILL, N.C., Nov. 25 /PRNewswir...that Prabhavathi Fernandes, president and chief ex... 21st Annual Health Care Conference at 8:50 a.m. E... in New York City. Dr. Fernandes will provide an ...linical programs for the treatment of drug-resista...
Breaking Medicine Technology:Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 4Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 5Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 6Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 7Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 8Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 9Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 10Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 11Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 12Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 13Swissray International Announces New Ownership 2Americans United for Life Action Says the House Approved Bill to Promote Abortion Overseas is a Grave Injustice 48545 1Scientists advance safety of nanotechnology 48543 1Scientists advance safety of nanotechnology 48543 2Scientists advance safety of nanotechnology 48543 3Favorable Vote From FDA Advisory Committee on SEROQUEL Pediatric Supplemental New Drug Applications 48541 1Favorable Vote From FDA Advisory Committee on SEROQUEL Pediatric Supplemental New Drug Applications 48541 2Favorable Vote From FDA Advisory Committee on SEROQUEL Pediatric Supplemental New Drug Applications 48541 3Favorable Vote From FDA Advisory Committee on SEROQUEL Pediatric Supplemental New Drug Applications 48541 4Favorable Vote From FDA Advisory Committee on SEROQUEL Pediatric Supplemental New Drug Applications 48541 5Favorable Vote From FDA Advisory Committee on SEROQUEL Pediatric Supplemental New Drug Applications 48541 6
...n-free results compared to,sumatriptan, RESEARCH T...,/PRNewswire-FirstCall/ -- -- Findings from two pi... sufferers demonstrated that,Trexima(TM) provided ...rs compared to placebo, and two through 24-hour su...proxen monotherapy. The,results were published tod...
...mmune, a,clinical stage nanomedicine company focus...tifunctional, tumor-targeted therapies has,been se...erican,Society of Clinical Oncology Annual Meeting... will take place from 8:00 am to 12,noon on June 3...sent the poster abstract entitled "Preliminary Res...
Other Medicine Technology:Trexima (Sumatriptan/Naproxen Sodium) Superior Efficacy Data,Published in JAMA 2Trexima (Sumatriptan/Naproxen Sodium) Superior Efficacy Data,Published in JAMA 3Trexima (Sumatriptan/Naproxen Sodium) Superior Efficacy Data,Published in JAMA 4Trexima (Sumatriptan/Naproxen Sodium) Superior Efficacy Data,Published in JAMA 5CytImmune To Present At ASCO Phase I Clinical Trial of CYT-6091 to,be Presented on June 3, 2007 2
(Date:11/28/2009)...s were more likely to consider change after 30-min... , FRIDAY, Nov. 27 (HealthDay News) -- A progr...why they should stop their dangerous behavior may ...archers have found. , The new study included 18...aired convictions, who were randomly assigned to o...
(Date:11/27/2009)...WNA, BC, Nov. 27 /PRNewswire/ - Uploadable USB ped...me time in wellness. A combination of advanced acc... are solving a long term concern over the accuracy...ately gauge and reward improved participation in a... one of the first wellness suppliers to integrate ...
(Date:11/27/2009)...HESTER, N.Y., Nov. 27 P... provider and fortunately every year, new vaccines...But do all vaccines boost immunity for the same pe...oster shots, needed to keep immunity strong? ,...l of the American Academy of Pediatrics, Michael P...
(Date:11/27/2009)...ling plus low-emission vehicles may reduce future ...AY, Nov. 27 (HealthDay News) -- Encouraging city d...would offer much greater public health benefits th...esearchers have found. , The study compared the...rban land transport scenarios for London, England,...
(Date:11/27/2009)... Multi-purpose bilingual coloring books ...se by the business community to educate - inform p... from Safety issues to Dinosuars to ABC,S and a ho...nt Louis, MO (PRWEB) November 27, 2009 -- Today&rs... toys to keep them busy any hour of the day, but o...
Breaking Medicine News(10 mins):Health News:Drunk Drivers May Respond to Brief Motivational Interview 2Health News:New USB technology adds accountability and convenience to wellness programs 2Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2
..., Safety and Efficacy Study of Zolpidem Tartrate S...wakening on an As-Needed Basis , , Evaluation of ...sive Compulsive Disorder , , RICHMOND, Calif., Ma...etary products that address important therapeutic ...
..., Videotape The Silliest Sneeze You,ve Ever Seen F...Little Allergies(R) Allergen Block! , , Contest E....Y., May 21 Do your friends, family, or coworkers...Allergen Block , announce the launch of the first ...
...Procedure doubles odds for intensive care compared... , THURSDAY, May 21 (HealthDay News) -- Babies...livery are nearly twice as likely to be admitted t...ion babies are also more likely to have breathing ...
..., LAS VEGAS, May 21 CPC of America, Inc. (OTC Bul...of its first patent of a synthetic sealant for spe... focused on the development and testing of the Med...on, CPC is focused on the development of its own s...
..., PRINCETON, N.J., May 21 Celator Pharmaceuticals...ch agreement with Cephalon, Inc. (Nasdaq: CEPH )...tion of the application of Celator,s proprietary t...echnology and expertise at Celator beyond our own ...
..., - Bold and innovative marketing campaign will ta...of use and excellent tolerability - , , CORONA, C...in generic and specialty branded pharmaceuticals, ...h symptoms of urge urinary incontinence, urgency, ...
Other Medicine News:Health News:Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association 2Health News:Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association 3Health News:Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association 4Health News:If Heads Turn When You Sneeze, Enter the 'Side-Splitting Sneeze Contest' 2Health News:Risk to Baby Rises With Repeat C-Sections 2Health News:Risk to Baby Rises With Repeat C-Sections 3Health News:CPC Files Patent for Synthetic Sealant for the MedClose(TM) Vascular Closure System (VCS) 2Health News:CPC Files Patent for Synthetic Sealant for the MedClose(TM) Vascular Closure System (VCS) 3Health News:Celator(R) Pharmaceuticals Initiates Research Agreement With Cephalon, Inc. 2Health News:Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB) 2Health News:Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB) 3Health News:Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB) 4
Reusable Template
MicroTouch LP (Low Profile) Stabilizer
Precision Stepper
SurePoint™ Stepper/Stabilizer EquipmentTable Mount
Medicine Products: